ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1016

Therapeutic Potential of Oxalobacter formigenes in CKD Development and Progression

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Xiong, Xiaozhong, NYU Langone Health, New York, New York, United States
  • Zaidan, Nadim, NYU Langone Health, New York, New York, United States
  • Cardozo, Lila, NYU Langone Health, New York, New York, United States
  • Charytan, Amalya M., NYU Langone Health, New York, New York, United States
  • Ho, Melody, NYU Langone Health, New York, New York, United States
  • Mishra, Arnav, NYU Langone Health, New York, New York, United States
  • Nazzal, Lama, NYU Langone Health, New York, New York, United States
  • Ambersley, Safirya, NYU Langone Health, New York, New York, United States

Group or Team Name

  • New York Institute of Technology College of Osteopathic Medicine.
Background

Cardiovascular events are the leading cause of death in chronic kidney disease (CKD) patients, but the mechanisms are poorly understood. Oxalate retention has been shown to induce systemic fibrosis and inflammation, contributing to CKD progression and cardiovascular complications in renal failure. Hydroxyproline is a common component of meats and a precursor of oxalate. Oxalobacter Formigenes (OxF) is a specialist oxalate degrader in the human intestines. We hypothesize that OxF colonization in CKD mice reduces oxalate levels and attenuates CKD progression and cardiovascular damage.

Methods

Twenty 5/6 nephrectomy (CKD) mice and 20 Sham-operated mice received a 1% hydroxyproline-supplemented diet for five months. 10 CKD and 10 Sham mice received one dose of OxF (1x109 CFU), and the other mice received culture medium as control. Mouse urine and blood were collected at different time points for measuring oxalate and creatine. All mice were sacrificed after five months, and their kidneys and hearts were harvested.

Results

Hydroxyproline supplementation induced kidney damage. Plasma oxalate and creatine level were increased in all mice. OxF treatment reduced plasma oxalate and creatine in both Sham and CKD groups. CKD mice had more severe inflammation and fibrosis in the kidney than Sham mice. OxF treatment ameliorated inflammation and fibrosis in both Sham and CKD mice. Perivascular fibrosis was found in the heart of CKD mice, but OxF-treated CKD mice displayed less perivascular fibrosis. RNA-seq of heart tissue revealed that the top altered genes and pathways in CKD compared to control mice were related to increased inflammation and fibrosis, decreased lipid metabolism, and increased lipid accumulation. However, OxF treatment reversed those pathways and genes altered in CKD control mice.

Conclusion

Hydroxyproline promoted CKD development and progression, likely through increased oxalate levels. OxF treatment attenuated CKD progression and ameliorated cardiovascular damage.

Funding

  • NIDDK Support